3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Squamous Cell Carcinoma of Head and Neck
11
Nasopharyngeal Carcinoma
6
Oropharyngeal Neoplasms
5
Prostatic Neoplasms
4
Laryngeal Neoplasms
4
Carcinoma
4
Mouth Neoplasms
3
Hypopharyngeal Neoplasms
3
Urinary Bladder Neoplasms
2
Rectal Neoplasms
2
Mesothelioma
2
Head and Neck Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Anus Neoplasms
2
Urothelial Carcinoma of the Bladder
1
Tongue Neoplasms
1
Stomatitis
1
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7
1
Salivary Gland Neoplasms
1
PSA Level Greater Than Two
1
Oligodendroglioma
1
Mesothelioma, Malignant
1
Meningioma
1
Lymphoma, Follicular
1
Lymphoid Interstitial Pneumonia
1
Locally Advanced Cervical Adenocarcinoma
1
HIV Infections
1
Glioma
1
Glioblastoma
1
Interventions
durvalumab
2
Tretinoin
2
Paclitaxel
2
Carboplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
STA 9090
1
SGN-LIV1A
1
Pemetrexed
1
MK 2206
1
Letrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Radiotherapy, Intensity-Modulated
×
30 days
×
Clear all
No trials found.